WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk ...

Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA (siRNA) drug reduced Lp(a) levels compared to placebo at ...

One in ten people in the UK have a needle phobia so serious it means they frequently miss out on vital treatments such as ...

Gene silencing is a negative feedback mechanism that regulates gene expression to define cell fate and also regulates metabolism and gene expression throughout the life of an organism. In plants, gene ...

Biologically active RNAs, including transport, ribosomal and small nuclear RNA (tRNA, rRNA, snRNAs) fold into unique structures guided by complementary pairing between nucleotide bases.